295 related articles for article (PubMed ID: 37107016)
1. What to Do with the New Antibiotics?
Chaïbi K; Jaureguy F; Do Rego H; Ruiz P; Mory C; El Helali N; Mrabet S; Mizrahi A; Zahar JR; Pilmis B
Antibiotics (Basel); 2023 Mar; 12(4):. PubMed ID: 37107016
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of the inoculum effect of new antibiotics against carbapenem-resistant enterobacterales.
Danjean M; Hobson CA; Gits-Muselli M; Courroux C; Monjault A; Bonacorsi S; Birgy A
Clin Microbiol Infect; 2022 Nov; 28(11):1503.e1-1503.e3. PubMed ID: 35777602
[TBL] [Abstract][Full Text] [Related]
3. Antimicrobial activities of ceftazidime/avibactam, ceftolozane/tazobactam, imipenem/relebactam, meropenem/vaborbactam, and comparators against Pseudomonas aeruginosa from patients with skin and soft tissue infections.
Sader HS; Castanheira M; Duncan LR; Mendes RE
Int J Infect Dis; 2021 Dec; 113():279-281. PubMed ID: 34670144
[TBL] [Abstract][Full Text] [Related]
4. New antibiotics for Gram-negative pneumonia.
Bassetti M; Magnè F; Giacobbe DR; Bini L; Vena A
Eur Respir Rev; 2022 Dec; 31(166):. PubMed ID: 36543346
[TBL] [Abstract][Full Text] [Related]
5. Novel Beta Lactam Antibiotics for the Treatment of Multidrug-Resistant Gram-Negative Infections in Children: A Narrative Review.
Venuti F; Romani L; De Luca M; Tripiciano C; Palma P; Chiriaco M; Finocchi A; Lancella L
Microorganisms; 2023 Jul; 11(7):. PubMed ID: 37512970
[TBL] [Abstract][Full Text] [Related]
6. Treatment of urinary tract infections in the era of antimicrobial resistance and new antimicrobial agents.
Bader MS; Loeb M; Leto D; Brooks AA
Postgrad Med; 2020 Apr; 132(3):234-250. PubMed ID: 31608743
[TBL] [Abstract][Full Text] [Related]
7. Activity of cefiderocol, imipenem/relebactam, cefepime/taniborbactam and cefepime/zidebactam against ceftolozane/tazobactam- and ceftazidime/avibactam-resistant Pseudomonas aeruginosa.
Lasarte-Monterrubio C; Fraile-Ribot PA; Vázquez-Ucha JC; Cabot G; Guijarro-Sánchez P; Alonso-García I; Rumbo-Feal S; Galán-Sánchez F; Beceiro A; Arca-Suárez J; Oliver A; Bou G
J Antimicrob Chemother; 2022 Sep; 77(10):2809-2815. PubMed ID: 35904000
[TBL] [Abstract][Full Text] [Related]
8. In Vitro Activity of Imipenem-Relebactam, Meropenem-Vaborbactam, Ceftazidime-Avibactam and Comparators on Carbapenem-Resistant Non-Carbapenemase-Producing Enterobacterales.
Bonnin RA; Bernabeu S; Emeraud C; Naas T; Girlich D; Jousset AB; Dortet L
Antibiotics (Basel); 2023 Jan; 12(1):. PubMed ID: 36671303
[TBL] [Abstract][Full Text] [Related]
9. Imipenem-Relebactam and Meropenem-Vaborbactam: Two Novel Carbapenem-β-Lactamase Inhibitor Combinations.
Zhanel GG; Lawrence CK; Adam H; Schweizer F; Zelenitsky S; Zhanel M; Lagacé-Wiens PRS; Walkty A; Denisuik A; Golden A; Gin AS; Hoban DJ; Lynch JP; Karlowsky JA
Drugs; 2018 Jan; 78(1):65-98. PubMed ID: 29230684
[TBL] [Abstract][Full Text] [Related]
10. Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli.
Zhanel GG; Golden AR; Zelenitsky S; Wiebe K; Lawrence CK; Adam HJ; Idowu T; Domalaon R; Schweizer F; Zhanel MA; Lagacé-Wiens PRS; Walkty AJ; Noreddin A; Lynch Iii JP; Karlowsky JA
Drugs; 2019 Feb; 79(3):271-289. PubMed ID: 30712199
[TBL] [Abstract][Full Text] [Related]
11. An Update on Eight "New" Antibiotics against Multidrug-Resistant Gram-Negative Bacteria.
Yusuf E; Bax HI; Verkaik NJ; van Westreenen M
J Clin Med; 2021 Mar; 10(5):. PubMed ID: 33806604
[TBL] [Abstract][Full Text] [Related]
12. Comparative activity of newer β-lactam/β-lactamase inhibitor combinations against Pseudomonas aeruginosa isolates from US medical centres (2020-2021).
Sader HS; Mendes RE; Arends SJR; Carvalhaes CG; Shortridge D; Castanheira M
Int J Antimicrob Agents; 2023 Apr; 61(4):106744. PubMed ID: 36738849
[TBL] [Abstract][Full Text] [Related]
13. Susceptibility of OXA-48-producing Enterobacterales to imipenem/relebactam, meropenem/vaborbactam and ceftazidime/avibactam.
Bonnin RA; Bernabeu S; Emeraud C; Creton E; Vanparis O; Naas T; Jousset AB; Dortet L
Int J Antimicrob Agents; 2022 Oct; 60(4):106660. PubMed ID: 35988666
[TBL] [Abstract][Full Text] [Related]
14. New β-Lactam-β-Lactamase Inhibitor Combinations.
Yahav D; Giske CG; Grāmatniece A; Abodakpi H; Tam VH; Leibovici L
Clin Microbiol Rev; 2020 Dec; 34(1):. PubMed ID: 33177185
[TBL] [Abstract][Full Text] [Related]
15. Clinical data from studies involving novel antibiotics to treat multidrug-resistant Gram-negative bacterial infections.
Kanj SS; Bassetti M; Kiratisin P; Rodrigues C; Villegas MV; Yu Y; van Duin D
Int J Antimicrob Agents; 2022 Sep; 60(3):106633. PubMed ID: 35787918
[TBL] [Abstract][Full Text] [Related]
16. In Vitro Activity of Imipenem/Relebactam and Ceftolozane/Tazobactam Against Clinical Isolates of Gram-negative Bacilli With Difficult-to-Treat Resistance and Multidrug-resistant Phenotypes-Study for Monitoring Antimicrobial Resistance Trends, United States 2015-2017.
Karlowsky JA; Lob SH; Raddatz J; DePestel DD; Young K; Motyl MR; Sahm DF
Clin Infect Dis; 2021 Jun; 72(12):2112-2120. PubMed ID: 32246147
[TBL] [Abstract][Full Text] [Related]
17. Cefiderocol, a Siderophore Cephalosporin, as a Treatment Option for Infections Caused by Carbapenem-Resistant Enterobacterales.
Kaye KS; Naas T; Pogue JM; Rossolini GM
Infect Dis Ther; 2023 Mar; 12(3):777-806. PubMed ID: 36847998
[TBL] [Abstract][Full Text] [Related]
18. Executive summary of the consensus document of the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC) on the diagnosis and antimicrobial treatment of infections due to carbapenem-resistant Gram-negative bacteria.
Pintado V; Ruiz-Garbajosa P; Aguilera-Alonso D; Baquero-Artigao F; Bou G; Cantón R; Grau S; Gutiérrez-Gutiérrez B; Larrosa N; Machuca I; Martínez Martínez L; Montero MM; Morte-Romea E; Oliver A; Paño-Pardo JR; Sorlí L
Enferm Infecc Microbiol Clin (Engl Ed); 2023; 41(6):360-370. PubMed ID: 36522272
[TBL] [Abstract][Full Text] [Related]
19. Synergistic Activity of Cefiderocol in Combination with Piperacillin-Tazobactam, Fosfomycin, Ampicillin-Sulbactam, Imipenem-Relebactam and Ceftazidime-Avibactam against Carbapenem-Resistant Gram-Negative Bacteria.
Palombo M; Bovo F; Amadesi S; Gaibani P
Antibiotics (Basel); 2023 May; 12(5):. PubMed ID: 37237761
[TBL] [Abstract][Full Text] [Related]
20. Multidrug-Resistant Pseudomonas Infections: Hard to Treat, But Hope on the Horizon?
Nguyen L; Garcia J; Gruenberg K; MacDougall C
Curr Infect Dis Rep; 2018 Jun; 20(8):23. PubMed ID: 29876674
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
